|
J Biol Chem, Vol. 273, Issue 20, 12633-12641, May 15, 1998
Transcriptional Regulation of Interleukin-1 Gene by
Interleukin-1 Itself Is Mediated in Part by Oct-1 in Thymic Stromal
Cells*
Yu-Hua
Tseng and
Linda A.
Schuler§
From the Program of Developmental Biology, Department of
Comparative Biosciences, University of Wisconsin,
Madison, Wisconsin 53706
 |
ABSTRACT |
Interleukin (IL)-1 is involved in many processes,
including thymic development. However, control of IL-1 expression in
thymic-derived stromal cells (TSC) has not been reported. We found that
IL-1 increased steady-state mRNA levels for IL-1 and IL-1
in TSC-936 and TSC-2C4 cells; stability was not a major determinant of
this effect. To study transcriptional regulation of IL-1 , we
functionally characterized 4 kilobase pairs of the 5'-flanking region
and first intron of the bovine IL-1 gene. The 470/+14 fragment was
sufficient to confer maximal responsiveness to IL-1 upon
transfection into these cell lines. Progressive 5' deletions identified
several IL-1 -responsive regions, including 308 to 226, which we
further characterized. Electrophoretic mobility shift and supershift
analyses showed that IL-1 induced the ability to form multiple
protein complexes with 261/ 226 and that one of these contained
nuclear factor Oct-1. A competitor containing a mutated Oct consensus site failed to compete not only for this complex but others as well,
suggesting that this sequence regulates binding of other proteins to
this region. Functional analysis confirmed that this element was
essential for maximal induction of transcription. These findings
document a heretofore undescribed mechanism utilized by TSC for
regulation of IL-1 transcription by IL-1 itself.
 |
INTRODUCTION |
The cytokine interleukin 1 (IL-1)1 mediates a wide
variety of inflammatory and hematopoietic processes. Although it is
primarily recognized as an inflammatory agent, it exerts diverse
effects on numerous cell types (for reviews, see Refs. 1-5). Two
distinct agonists, IL-1 and IL-1 , are encoded by distinct but
closely related genes, and are produced by several cell types.
Monocytes are the major sources of IL-1 in response to components
derived from infectious agents such as lipopolysaccharide (LPS), and
much of our knowledge about the control of IL-1 expression has been derived from these cells.
In addition to its well known function in inflammation, IL-1 also plays
an important role in T-cell development (for reviews, see Refs. 6 and
7). In the thymus, thymic stromal cells (TSC) produced a number of
cytokines, including IL-1. IL-1 has been described as a co-mitogen for
some populations of immature thymocytes (8-10) and prevents apoptosis
(11). IL-1 and tumor necrosis factor- were shown to be required
for early thymocyte commitment and differentiation (12), and IL-1
was shown to be essential for positive selection by thymic nurse cells
(13). In addition to effects on thymocytes, IL-1 also induced DNA
synthesis and morphological changes in TSC (14) and stimulated thymic epithelial cells to produce other cytokines, such as IL-6, IL-8, granulocyte/macrophage-colony stimulating factor, and leukemia inhibitory factor (15-17). These studies suggest that TSC-derived IL-1
serves as an autocrine/paracrine factor to modulate cytokine production
within the thymus. A number of growth factors and hormones have been
shown to regulate IL-1 expression in TSC, including epidermal growth
factor, transforming growth factor- (18, 19), growth hormone, and
prolactin (20). However, despite its biological significance, the
regulation of IL-1 expression at the transcriptional and
post-transcriptional levels in TSC remains poorly understood.
IL-1 has been shown to induce the expression of its own gene in several
cells, including mononuclear cells (21), vascular smooth muscle cells
(22), vascular endothelial cells (23), thymoma cells (24), and dermal
fibroblasts (25). Whether it exerts a similar autocrine effect in other
cells such as TSC has not been examined. Although transcriptional
control has been implicated in some studies, little is known about the
mechanism(s) of the response.
The regulation of IL-1 transcription has been most extensively studied
in response to LPS in monocytes (for reviews, see Refs. 1, 3, and 26).
Several DNA regulatory elements and corresponding nuclear proteins have
been identified, which ultimately participate in the control of IL-1
transcription. These include an upstream induction sequence, which
binds transcription factors NF-IL6, cAMP-response element binding
protein (27), NF- B (28) and a STAT-like factor (24), and
promoter-proximal regulatory elements containing binding sites for
NF-IL6 (29, 30) and a B-cell and myeloid-specific transcription factor
PU.1 (Spi-1, NF- A; Refs. 31 and 32). In addition to transcriptional
regulation, the stability of IL-1 mRNA can be selectively modulated
by various stimuli (for review, see Ref. 26). Little is known about how this gene is controlled in other cell types by different stimuli. Moreover, several lines of evidence have suggested that regulation of
IL-1 expression may occur at multiple levels, and the mechanisms may
vary with the particular cell type and stimulus examined (18, 20,
33-37).
In this study, we show that IL-1 is able to increase levels of
mRNAs for both IL-1 and IL-1 in TSC, documenting a positive feedback loop for IL-1 in the thymus. We show that IL-1 regulates its own gene primarily at the level of transcription by inducing Oct-1
binding to a consensus sequence in the 5'-flanking region. These
findings describe a previously unrecognized mechanism for autocrine
regulation of IL-1 in TSC and establish a model system to study IL-1
gene regulation and signal transduction.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Recombinant bovine IL-1 was a generous gift
from Dr. Dale Shuster, American Cyanamid Company, Princeton, NJ. LPS
and actinomycin D were purchased from Sigma. Antibodies, anti-Oct-1
(sc-232x), and anti-STAT5b (sc-835x) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Tissue culture plates and flasks were
obtained from Fisher.
Cell Culture and Induction--
Three bovine thymic stromal cell
lines (TSC-936, TSC-2C4, TSC-934) and a bovine endometrial fibroblast
line (End-6.2) were generated by a strategy of temperature-sensitive
conditional transformation as described previously (20, 38). Previous
immunocytochemical studies showed that both TSC-936 and TSC-2C4 cells
stained positively only for vimentin, consistent with a mesenchymal
origin, whereas TSC-934 cells exhibited both vimentin- and
cytokeratin-specific staining (Ref.
20).2 Growth of these cells
resembles tumor cells at the permissive temperature (33 °C) and
reverts to a normal phenotype at the nonpermissive temperature
(39 °C), which is also the normal temperature for bovine cells.
These cells were routinely maintained at 33 °C in Dulbecco's
modified Eagle's medium/F-12 (Life Technologies, Inc.), 100 units/ml
penicillin G, 100 µg/ml streptomycin (Life Technologies, Inc.), and
5% fetal bovine serum (Hyclone; Logan, UT). LB, a bovine dermal
fibroblast line (39), was grown at 39 °C. All experiments were
performed on cells within 20 passages. For stimulation with cytokine,
cells were plated and grown at 39 °C for 3 days to 80-90% confluency. The cells were then washed with Dulbecco's
phosphate-buffered saline (DPBS, Life Technologies, Inc.) twice and
serum-starved for 24 h in Dulbecco's modified Eagle's medium/F12
before treatment. In all experiments, cells were treated with IL-1
at 10 ng/ml (0.5 nM) unless otherwise noted. LPS was used
at 10 µg/ml. For mRNA stability studies, cells were treated with
IL-1 for 3 h followed by the addition of 2 µg/ml actinomycin
D, and incubation was continued for varying times.
RNA Purification and Northern Analysis--
Cells were plated at
a density of 4 × 105/T-25 flask and grown at 39 °C
for 3 days before serum starvation and cytokine treatment as described
above. Total RNA was isolated and analyzed using methods described
previously (20). The signals were quantified with a PhosphorImager
Storm 840 (Molecular Dynamics, Sunnyvale, CA). All determinations were
repeated 2-3 times.
Genomic Library Screening and DNA Sequencing--
A bovine
genomic EMBL3 phage library (40) was screened with an oligonucleotide
probe (5'-GCAATGAAGGTTGGCTGG-3') made from the 5'-untranslated region
of the bovine IL-1 cDNA (41). Nucleotide sequences were
determined on both DNA strands and analyzed using the Genetics Computer
Group programs (42).
Plasmid Constructions--
The 4-kbp
BamHI/BamHI fragment with or without an
additional 0.6-kbp BamHI/NcoI fragment was
inserted into pGL3-basic (Promega) to generate the pIL-1 -luciferase
constructs with or without the first intron (Fig. 4, constructs 1 and
2). Other deletion constructs were generated by digestion with
appropriate restriction enzymes from these plasmids. 278/+14,
255/+14, and -234/+14 constructs (Fig. 5) were derived by polymerase
chain reaction amplification using oligonucleotides corresponding to
the specific regions. Site-directed mutagenesis was carried out using a
mutagenic oligonucleotide (5'-CCAACATATgcTTGCATGATGACAC-3'; sequences
correspond to 247 to 223 of the bovine IL-1 gene, and the
lowercase letters indicate mutated bases) and the MORPHTM
site-specific plasmid DNA mutagenesis kit (5 Prime 3 Prime, Inc.,
Boulder, CO) to introduce an AT to GC mutation in the Oct consensus
site in the 303/+14 and 255/+14 reporter plasmids. All constructs
were confirmed by DNA sequencing. Plasmid DNAs used for transfection
were prepared using the Qiagen plasmid kit (Qiagen, Inc., Chatsworth,
CA).
Transfections and Reporter Gene Assay--
Transfections were
performed by the calcium phosphate method modified from Kingston
et al. (43). For transient transfections, TSC-2C4 cells were
plated at 3.6 × 105/6-cm plate and grown at 39 °C
for 3 days. After transfection, they were washed with Dulbecco's
phosphate-buffered saline three times, incubated in serum free
Dulbecco's modified Eagle's medium/F12 for 12-16 h, and then
stimulated with 0.5 nM IL-1 for an additional 24 h
before harvesting. Cells were lysed with 110 µl of 1× cell culture
lysis reagent (Promega). Luciferase activity was measured by adding 100 µl of luciferase substrate to 50 µl of cell lysate in a Turner
Designs Model 20/20 luminometer (Turner Designs, Sunnyvale, CA).
Relative light units were determined by 10-s integration and normalized
with the co-transfected -galactosidase activity, as measured by the
Galacto-Light Plus kit (Tropix Inc., Bedford, MA).
TSC-936 cells were stably transfected pIL-1 -luciferase constructs
and pcDNA3 (Invitrogen, San Diego, CA) encoding the neomycin resistance gene and selected in 0.3 mg/ml G418 (Life Technologies, Inc.)-containing medium. Expanded, resistant colonies were treated as
above. Luciferase activity was corrected for protein, as determined by
the BCA protein assay (Pierce).
Preparation of Nuclear Extracts--
TSC-2C4 and TSC-936 cells
were plated at a density of 1.8-2 × 106/10-cm plate
and grown at 39 °C for 3 days before serum starvation and cytokine
treatment as described above. Nuclear extracts were prepared by a
method modified from Andrews and Faller (44). Cells from two 10-cm
plates were incubated on ice for 10 min in 400 µl of buffer
containing 10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, and 2 mM Na3VO4,
vortexed, and then pelleted. A high salt extraction was performed by
resuspending the cells in 25 µl of buffer containing 20 mM HEPES, pH 7.9, 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl
fluoride, 2 µg/ml aprotinin and incubating on ice for 30 min. The
extraction was repeated, and the supernatants were pooled and stored at
80 °C. Protein concentrations were determined by the BCA protein
assay.
Electrophoretic Mobility Shift Analysis (EMSA)--
Mobility
shift reactions containing 5 µl of nuclear extract (5 µg of total
protein), 3 µg of poly(dI·dC), 4 µl of 5× binding buffer (1×
contains 10 mM HEPES, pH 7.9, 10% glycerol, 50 mM KCl, 2.5 mM MgCl2, 0.1 µg/ml
bovine serum albumin, 1 mM dithiothreitol), and 1 ng of
double-stranded oligonucleotide probe labeled by T4 polynucleotide
kinase purified by Nick Columns (Amersham Pharmacia Biotech) in a final
volume of 20 µl were incubated at room temperature for 20 min. The
reactions were electrophoresed for 1.5-2 h on a 4% polyacrylamide gel
with 2.5% glycerol in 0.25× Tris-buffered EDTA that had been prerun
for at least 1 h. The 308/ 226 fragment (Fig. 5D)
was generated by polymerase chain reaction amplification followed by
gel purification. The 308/ 274 and 261/ 226 oligonucleotides (Fig. 5D) were synthetic double-stranded DNA. For the
competition assays, a 100-fold excess of competitor oligonucleotides
was added to the binding reaction 20 min before the addition of the
radiolabeled probe. Consensus sequences (CS) used as specific
competitors include Oct_CS, 5'-CGTACGTCCATTTGCATGGATCCTCT-3'
(45); GATA_CS, 5'-GAAACAAGATAAGATCAAATT-3' (46); PRE,
5'-AGATTTCTAGGAATTCAAATC-3' (47); and mu 261/ 226, 5'-AGTTGTCAGAAAAACCAACATATgcTTGCATGATGA-3' (lowercase letters indicate mutated bases). For supershift assays, extracts were preincubated with 1 µg of antibody for 45 min at room temperature before the addition of the radiolabeled probe. All experiments were
repeated at least two times.
 |
RESULTS |
Induction of IL-1 and IL-1 mRNAs by IL-1 in Thymic
Stromal Cells--
To see if there are differences in the ability of
IL-1 to induce IL-1 expression among fibroblast cell lines derived from different tissues, we examined the effects of IL-1 on both IL-1 agonist mRNAs in different cell lines by Northern analysis. To eliminate the possibility that hormones or growth factors present in
serum may induce the expression of IL-1, cells were cultured in
serum-free media for 24 h before treatment. No IL-1 RNA was detected in any unstimulated cells (Fig.
1). IL-1 induced both IL-1 and
IL-1 mRNA accumulation in all three thymic stromal cell lines
(TSC-934, -936, -2C4) to a somewhat different extent. IL-1 increased
only IL-1 mRNA in the endometrial stromal End-6.2 cells.
However, IL-1 had no detectable effect on mRNA levels for either
IL-1 agonist in the LB line, despite the fact that IL-1 receptors have
been described on these cells (48). In contrast to monocytes, the
thymic stromal cell lines TSC-936 and TSC-2C4 were insensitive to LPS
stimulation. This also ruled out the possibility that the IL-1
responses we observed were due to endotoxin contamination in the
recombinant cytokine. These data suggested that the ability of IL-1
to induce IL-1 and IL-1 mRNAs was cell-specific.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
Induction of IL-1 and IL-1 mRNAs by
IL-1 in different cell lines. Cells were treated for 1 or
5 h with IL-1 ( ), LPS (L), or an equivalent
volume of medium (M). 3.5 µg of total RNA were subjected
to Northern analysis for IL-1 and IL-1 . The blots were reprobed
with cDNA for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) to normalize for variations in loading and transfer
of RNA. Representative blots are shown.
|
|
To further investigate the effects of IL-1 on thymic-derived stromal
cells, we focused on cell lines TSC-936 and TSC-2C4. In both cell
lines, IL-1 mRNA was greatly increased as early as 1 h by
IL-1 , but increases in the level of IL-1 mRNA were not
observed until 3 h after the addition of cytokine (Fig.
2, A and B).
However, at longer times, relative transcript levels differed between
these cell lines. In TSC-936 cells, both messages gradually declined
with time, whereas in TSC-2C4 cells, a further rise was observed at
8 h for both IL-1 and IL-1 , and levels remained elevated at
24 h.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 2.
Regulation of IL-1 and IL-1 mRNAs
by IL-1 in TSC-936 (panels A and C) and
TSC-2C4 (panels B and D). A and
B, time courses for the induction of IL-1 and IL-1
mRNAs by IL-1 . Cells were treated with IL-1 for increasing
times and then harvested for determinations of IL-1 and IL-1
mRNA levels. C and D, regulation of IL-1
and IL-1 mRNA stability by IL-1 . Cells were treated with
IL-1 for 3 h, then actinomycin D (Act-D) was added.
Total RNA was isolated at 0, 0.5, 1, 2, and 4 h after the addition
of actinomycin D, and Northern analyses were performed as described in
Fig. 1. Representative blots are shown. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
|
|
Regulation of IL-1 and IL-1 mRNA
Stability--
Expression of the IL-1 and IL-1 genes is
regulated at multiple levels, including both transcriptional and
post-transcriptional mechanisms. To assess the contribution of mRNA
stability to the IL-1 -induced increases in steady-state levels of
IL-1 and IL-1 mRNAs, we measured the rates of decay of these
transcripts following IL-1 treatment after inhibiting new
transcription with actinomycin D. As shown in Fig. 2, C and
D, both IL-1 and IL-1 mRNA rapidly decayed in both
cell lines, with an estimated half-life of less than 1 h, similar
to that reported for many unstable mRNAs in different cell types
(for review, see Ref. 49). These data suggested a role for
transcriptional regulation in the changes in steady-state levels of
mRNA that we observed.
Cloning of the Bovine IL-1 5'-Flanking Region--
As a first
step toward studying the transcriptional regulation of IL-1 gene by
IL-1 itself, we cloned the bovine IL-1 gene and functionally
characterized the 5'-flanking region. A genomic clone with a 12-kbp
SalI insert was isolated that contained about 7 kbp of
5'-flanking region plus the coding sequences. Primer extension
identified a major transcript with an initiation site 45 base pairs 5'
to the first exon-intron junction; a TATA box was located 25 base pairs
upstream of this site. Multiple other minor start sites were also
observed in TSC-936, TSC-2C4, and peripheral blood mononuclear cells
(data not shown), consistent with the multiple putative TATA boxes
present in the 5'-flanking region of this gene (Fig.
3A). Consensus sequences for a
number of putative transcription factors were present in the
5'-flanking region as well as the first intron. Comparison of the
sequences of the proximal promoter region ( 462 to +45) to the human
genomic sequences (50) showed 76% identity, including the regions
indicated in IL-1 responsiveness (Fig. 3B).

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 3.
Bovine IL-1 5'-flanking DNA sequences.
A, nucleotide sequence of the bovine IL-1 gene from
1210 to +685 (GenBank/EMBL accession number AF026543). Base pairs are
numbered according to the transcription start site (arrow).
Relevant restriction enzyme sites are circled. Sequences
with a perfect match to a consensus transcription factor binding site
are underlined. Putative TATA boxes with either zero or one
mismatch from published consensus sequences are shown as
boxes. Exons are shown in capital letters. The
translation initiation site (ATG) is shown in bold.
B, comparison of bovine (top) and human
(bottom; GenBank/EMBL accession number M15840) IL-1
promoter proximal region sequences. Sequences extending from 308 to
226 of the bovine IL-1 5'-flanking region are compared with the
corresponding human IL-1 genomic sequences. Vertical
lines denote conserved nucleotides. Putative transcription factor
sites are boxed.
|
|
Identification of IL-1 -responsive Elements in the IL-1
5'-Flanking Region--
To determine the role of transcription in the
IL-1 -induced increases in the steady-state levels of mRNA, a
fragment containing 4 kbp of the 5'-flanking region plus the first
intron was linked to the luciferase reporter gene, and this construct
was transiently transfected into TSC-2C4 cells. Stimulation of the
cells with IL-1 increased luciferase activity 3.7-fold (Fig.
4, C and D, lane 1). To further localize sequences necessary for IL-1
autoregulation, we generated a series of 5'-deletion constructs
containing different amounts of the 5'-flanking region with or without
the first intron (Fig. 4A) and examined their responsiveness
in both TSC-2C4 and TSC-936 cells. Because TSC-936 cells were difficult
to transiently transfect, we generated stably transfected cells. To
normalize for different copy numbers of the foreign gene in different
stable cell lines, data are presented as -fold induction by IL-1
relative to the medium control. In both stably transfected TSC-936 and transiently transfected TSC-2C4, the 470/+14
EcoRI-BamHI fragment was sufficient to confer
maximal responsiveness to IL-1 (Fig. 4, B-D, lane
6). Basal levels varied with different constructs in transiently
transfected TSC-2C4 (Fig. 4C), suggesting multiple positive
and negative regulatory elements. The stimulatory effect of IL-1 was
dose-dependent; increases in luciferase activity were
observed at concentrations as low as 20 pM, reaching
maximal levels at 0.5 nM in both cell lines (data not
shown).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 4.
Functional characterization of the IL-1
5'-flanking region. A, structural organization of 4 kbp of
the 5'-flanking region and the first intron of the bovine IL-1 gene.
A series of deletion constructs were made containing different lengths
of the 5'-flanking region with or without the first intron in the
promoterless luciferase reporter gene vector pGL3-basic. All the
constructs were either stably transfected into TSC-936 cells
(B) or transiently transfected into TSC-2C4 cells
(C and D), and IL-1 responsiveness was
examined as described under "Experimental Procedures." In
panel C, results are presented as the luciferase activity in
IL-1 -stimulated cells (black bars) and untreated medium
control (white bars). In panels B and
D, data are presented as Fold-Induction by
IL-1 relative to the medium control for each construct. Values were
obtained from a minimum of three independent experiments, with each
treatment group represented by duplicate plates; error bars
indicate the S.E. of the mean. RLU, relative light
units.
|
|
Because similar response patterns were observed in both cell lines, we
utilized transiently transfected TSC-2C4 cells to further localize the
response elements. Progressive 5' deletions of the 470/+14
EcoRI/BamHI fragment identified several
IL-1 -responsive regions (Fig. 5,
A-C). Deletion of 303 to 234 reduced IL-1 -stimulated reporter gene activity from 6.6- to 1.9-fold. Further dissection of
this region identified two smaller areas located at 303 to 278 and
255 to 234, each of which reduced IL-1 responsiveness by
approximately 40%. There was no significant difference between the
constructs 278/+14 and 255/+14, suggesting that 278 to 255 may
not contain important elements for the IL-1 response. Another
region, located between 180 and 100, appeared to contain elements
responsible for both basal and IL-1 -induced activities. In fact,
deletion of 234 to 180 showed a significant reduction in basal
activity, and further deletion to 100 diminished basal transcription
to that of the promoterless vector control (Fig. 5B). To
avoid the confounding influence of basal transcription on
IL-1 -induced activity, we focused our studies on the 303 to
234 region.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 5.
Localization of IL-1-responsive elements in
the 470/+14 EcoRI/BamHI fragment of the
IL-1 gene. A, a series of deletion constructs were made
from the 470/+14 fragment of the IL-1 5'-flanking region in the
promoterless luciferase reporter gene vector pGL3-basic. All constructs
were transiently transfected into TSC-2C4 cells, and IL-1
responsiveness was examined as described under "Experimental
Procedures." Values were obtained from a minimum of three independent
experiments with each treatment group represented by duplicate plates;
error bars indicate the S.E. of the mean. B,
luciferase activity in IL-1 -stimulated cells (black bars)
and untreated medium control (white bars). C,
Fold induction by IL-1 relative to the medium control for each
construct. D, nucleotide sequence of the 308/ 226 region.
Putative response elements for known transcription factors are
boxed. Horizontal lines beneath the sequence show
the fragments used as probes in EMSA.
|
|
Characterization of Protein Complexes That Bind to the 308/ 226
Region--
To visualize protein-DNA interactions within the
303/ 234 region, EMSA was performed. Using a probe spanning 308 to
226 (Fig. 5D), which included the 303/ 234 fragment and
some surrounding sequences, we examined complex formation in nuclear
extracts prepared from TSC-2C4 cells stimulated with IL-1 for
increasing times. As shown in Fig.
6A, extracts from the
IL-1 -stimulated cells were able to form at least five complexes.
Among these, complex 2 was not detected in the untreated cells and was
strongly induced by IL-1 . Complexes 1 and 3 were present at low
levels before treatment and further increased by IL-1 . These
complexes were induced by IL-1 as early as 30 min and remained
intact up to 9 h. Competition assays showed that all five
complexes were specifically competed by excess unlabeled 308/ 226
oligonucleotide (Fig. 6B, lane 2). The
oligonucleotide, PRE, containing the consensus site for transcription
factor STAT5 (47) was used as a nonspecific control because it had no
sequence homology to the 308/ 226 fragment. Only complex 4 was
competed by PRE, suggesting that this complex is nonspecific (Fig.
6B, lane 5). Nuclear extracts from
IL-1 -treated TSC-936 cells yielded a very similar pattern (data not
shown). To determine which region of the DNA was responsible for the
specific binding, oligonucleotides 308/ 274 and 261/ 226,
containing the two IL-1 -inducible regions described in Fig. 5, were
used as competitors. We found that oligonucleotide 261/ 226
effectively competed for binding in complexes 1, 2, and 3 (Fig.
6B, lane 4), whereas a 100-fold excess of the
308/ 274 fragment only weakly competed for binding in complexes 1 and 3 (Fig. 6B, lane 3). Based on these results,
we pursued identification of the proteins binding to the 261/ 226
region.

View larger version (71K):
[in this window]
[in a new window]
|
Fig. 6.
Induction of protein complexes binding to the
308/ 226 region of the IL-1 gene by IL-1 . A, EMSA
with the radiolabeled 308/ 226 probe and nuclear extracts prepared
from TSC-2C4 cells treated with IL-1 ( ) or an equivalent volume
of medium (M) for 0.5, 2, and 9 h. B, EMSA
with the 308/ 226 probe and nuclear extracts prepared from TSC-2C4
cells treated with IL-1 for 2 h with or without a 100-fold
excess of nonradiolabeled competitor oligonucleotides. Numbered
arrows on the left indicate different protein-DNA complexes.
Representative gels are shown.
|
|
IL-1 -induced Nuclear Factor Oct-1 Binding to the 261/ 226
Region--
EMSA with the 261/ 226 oligonucleotide probe identified
multiple complexes formed after IL-1 treatment (Fig.
7). Similar to the pattern of complexes
observed with the 308/ 226 probe, binding was detected after 30 min
of IL-1 treatment and remained elevated after 9 h of cytokine
exposure (data not shown). IL-1 specifically induced the ability to
form complexes 1, 2, 3, and 5 at all the time points we examined. A
faint band of lower mobility was detectable in some experiments.
Complex 5 may contain some nonspecific proteins because a 100-fold
excess of the 261/ 226 oligonucleotide itself was not able to
completely abolish the signal (Fig. 7A, lane 3).
This may also be due to phosphatases present in the nuclear extracts
that may interact only with phosphorylated probes but not cold
competitors (51). Complex 4 appeared to be nonspecific because it was
competed by PRE (Fig. 7A, lane 7).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 7.
Identification of the IL-1 -induced factors
binding to the 261/ 226 region of the IL-1 gene. A and
C, EMSA with the 261/ 226 probe and nuclear extracts
prepared from TSC-2C4 cells treated with medium (A,
lane 1) or IL-1 for 2 h with or without a 100-fold
excess of nonradiolabeled competitor oligonucleotides. B,
supershift analysis by preincubation of the nuclear extracts without
(lane 1) or with 1 µg of anti-Oct-1 (lane 2) or
an equal amount of anti-STAT5 as a nonspecific control (lane
3). Numbered arrows on the left indicate different
protein-DNA complexes. Representative gels are shown.
|
|
Sequence analysis of the 261/ 226 region revealed a number of
potential regulatory elements including a perfect Oct consensus site
(52, 53) and two GATA-like elements with one mismatch from published
consensus sequences (Ref. 54 and Fig. 5D). To determine
whether these sequence elements were involved in the formation of
IL-1 -induced complexes, oligonucleotides containing the consensus
sites for Oct (45) or GATA (46) factors were used as competitors in
EMSA. As seen in Fig. 7A, Oct consensus oligonucleotides
effectively blocked formation of complex 1 and slightly reduced the
intensity of complexes 2 and 3 (Fig. 7A, lane 5).
The identity of the Oct factor in complex 1 was confirmed by supershift
analysis. Anti-Oct-1 specifically supershifted complex 1 (Fig.
7B, lane 2), whereas the control anti-STAT5
failed to shift the mobility of any complex (Fig. 7B,
lane 3). To further explore the role of the Oct consensus
sequence in protein binding to the 261/ 226 fragment, an
oligonucleotide (mu 261/ 226) containing an AT to GC mutation (55) in
the Oct consensus site of the 261/ 226 fragment was used in the
competition assay. The mu 261/ 226 oligonucleotide not only failed to
compete in the formation of complex 1 but also failed to compete
completely for binding in the other specific complexes (Fig.
7C, lane 3, compared with the competition with the original 261/ 226 oligonucleotide, lane 2). In fact,
mu 261/ 226 only slightly reduced the intensity of complex 3.
To determine the contribution of the Oct element in autocrine
regulation of IL-1 transcription, functional analyses were performed
using mutated promoters, 303 to +14 and 255 to +14. A significant
reduction in reporter gene activity was seen in cells transfected with
either construct carrying an AT to GC mutation in the Oct consensus
site compared with the wild-type construct (Fig.
8). However, basal levels of
transcription were not affected by the mutation. Taken together, these
data suggest a critical role for Oct-1 in IL-1 transcriptional
regulation of the IL-1 gene.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 8.
Functional analysis of the Oct consensus site
in IL-1 -induced transcription. A, results are shown as
luciferase activity in IL-1 -stimulated cells (black bars)
and untreated medium control (white bars). B,
data are presented as fold induction by IL-1 relative to the medium
control for each construct. Mutation constructs were generated, and
luciferase assays were performed as described under "Experimental
Procedures." Values were obtained from four (constructs 303/+14 and
303/+14muOct) or three (constructs 255/+14 and 255/+14muOct)
independent experiments, with each treatment group represented by
duplicate plates; error bars indicate the S.E. of the mean.
Significance was determined relative to corresponding wild-type control
by ordinary ANOVA (post test is the Student-Newman-Keuls multiple
comparisons test). *** = p < 0.001; * = p < 0.05; RLU, relative light units.
|
|
A GATA consensus oligonucleotide competed for some, but not all, of the
binding activity in complexes 3 and 5 (Fig. 7A, lane 6), suggesting that GATA factors may be involved in the IL-1 response. In addition, we found that oligonucleotide 308/ 274 was
able to compete for binding to complex 3 and part of complex 5 (Fig.
7A, lane 4), suggesting that 261/ 226 and
308/ 274 share some common binding factors.
 |
DISCUSSION |
We have demonstrated that IL-1 increases mRNAs for both
IL-1 agonists in TSC, providing a potential autocrine-paracrine
positive feedback loop for IL-1 activity in the thymic
microenvironment. This effect appears to be cell-specific, since the
expression patterns we observed differed in stromal cell lines derived
from different tissues as well as from those described in other cell types. The mechanism by which IL-1 exerts this effect appears to be
primarily at the level of transcription, despite the major role for
modification of mRNA stability in control of gene expression for
these cytokines in other cells (26, 49). Our investigation of the
IL-1-induced increase in transcription of the IL-1 gene in TSC
revealed a different mechanism than has been described for IL-1 action
on other target genes in other cells types and required distinct
sequences in the 5'-flanking region of the IL-1 gene than have been
described in the response to other agents. In TSC, this involves a
member of the pit, oct, unc (POU) domain family of transcription
factors, Oct-1, binding to an Oct consensus element positionally
conserved in the IL-1 gene across species.
Oct-1 is a widely expressed member of the POU domain family of
transcription factors. POU factors contain two highly conserved domains, a POU-specific domain and a POU homeodomain, which mediate binding to DNA as well as interactions with other proteins that contribute to regulation of transcription (for reviews, see Refs. 52
and 53). Oct-1 has been shown to regulate transcription of a number of
housekeeping as well as some tissue-specific and developmentally
regulated genes, such as small nuclear RNA, H2B, Pit-1 (56),
immunoglobulin genes (57), and several cytokine genes, including IL-2
(58), IL-3, IL-5, granulocyte/macrophage-colony stimulating factor
(59), and IL-8 (60). It may inhibit (Pit-1, IL-8) or stimulate (the
others) transcription of these target genes; accumulating evidence
indicates this is dependent on sequence context, allowing interactions
with other transcription factors or regulators.
In TSC, we found that the binding activity of Oct-1 to sequences in the
5'-flanking region of the IL-1 gene was specifically induced by
IL-1 , and our functional analysis confirmed an essential role of
this mechanism in mediating the response. Oct-1 did not appear to play
a role in determining basal transcription of IL-1 in TSC, in
contrast to the role of Oct-1 in regulation of some of the cytokine
genes noted above (59, 60). The role of Oct-1 in IL-1 autocrine
regulation and other IL-1 actions in other cell types remains to be
determined. Factors not implicated in the present studies appear to be
involved in IL-1-stimulated IL-1 gene transcription in some cells.
Tsukada et al. (24) have shown that in the murine EL4
thymoma cell line, IL-1 induced binding of a STAT-like factor to the
LPS and IL-1-responsive element located at position 2863 to 2841 of
the human IL-1 gene. The 4- to 0.5-kbp region was not implicated
in the IL-1 response in our cells, nor were we able to detect any
IL-1 -induced complex formation in TSC using EMSA with consensus
sequences for STAT 1, 3, or 5.2 In addition, IL-1 does not
stimulate Oct-1 activity in all systems. It has been reported that
IL-1- in combination with cycloheximide or actinomycin D could not
superinduce the binding activity of Oct-1 in A549 cells (61), and in
Caco-2 and HepG2 epithelial cell lines, IL-1 treatment resulted in
removal of Oct-1 from the IL-8 promoter, where it functions as a
repressor (60). Taken together, our findings and these reports are
consistent with different mediators of IL-1 action depending on the
target cell as well as complex regulation of the activity of Oct-1 by
IL-1 , which is dependent on promoter sequence and cell context.
In the mobility shift assays, we found that the IL-1 -induced
complexes were formed as early as 30 min. This rapid response suggested
that IL-1 may activate the participating protein factors through a
post-translational mechanism, such as phosphorylation or
dephosphorylation. Phosphorylation has been shown to increase or
decrease the activity of POU domain transcription factors in a
site-specific manner (52, 53). Several of the multiple kinases and
phosphatases that have been demonstrated to be activated by IL-1 in
different systems (for reviews, see Refs. 2 and 62) have been
implicated in control of the activity of Oct-1, including protein
kinase A (63, 64) and protein kinase C (63). Phosphorylation of Oct-1
at S-385 in the POU homeodomain inhibited DNA binding to the H2B
promoter (64), and inhibition of phosphatases resulted in decreased
Oct-1 binding to DNA by EMSA using extracts from the B-cell Daudi cell
line (63). Of note, pretreatment with the phosphatase inhibitor sodium
orthovanadate blocked IL-1 induction of IL-1 transcription in
TSC.2 However, our observed recruitment of Oct-1 to the
DNA-protein complex in response to IL-1 may not necessarily be a
result of modification of Oct-1 itself but rather an accessory protein
that then facilitates Oct-1 binding. Additional studies to examine IL-1-induced modifications of Oct-1 and the IL-1 signaling cascade in
TSC as well as other IL-1 target cells are necessary to clarify the
mechanism and cell/target gene specificity.
The POU domain also provides an interface for interactions with other
proteins. Many cellular as well as viral factors have been shown to
associate with Oct-1 in response to different stimuli (52, 53). In our
studies in TSC, we found that an oligonucleotide containing a mutation
in the Oct consensus site not only failed to abolish formation of the
Oct-1-containing complex but also failed to compete for the other
complexes formed with the 261/ 226 probe, suggesting that binding of
Oct-1 was required for binding of additional proteins to this DNA.
Involvement of the GATA family of transcription factors suggested by
our data provides candidates to study these interactions. The
308/ 274 region, adjacent to the region containing the Oct consensus
site, contains three additional GATA-like response elements. These
sequences were also able to compete for some protein binding to the
261/ 226 probe, suggesting that GATA proteins could be common
factors shared by these two regions. GATA factors have been most
studied for their roles in regulation of hematopoiesis (54, 65), but
this growing family of transcription factors has recently been found to
play tissue-specific roles in multiple other cell types (66-68). Like
the POU family of transcription factors, recent evidence indicates that
interactions with other cell-specific proteins may modulate their
activities (69).
The demonstration in this study that IL-1 increased levels of both
IL-1 and IL-1 mRNAs in TSC implies a role for IL-1 in
regulating cytokine production in the thymus, contributing to T-cell
development. We used this system to study IL-1 regulation of IL-1
transcription and identified several responsive regions in the
5'-flanking region of the bovine IL-1 gene. Our data demonstrated that IL-1 stimulated transcription in part through the nuclear factor Oct-1 binding to an Oct consensus element in these cells. Identification of additional regulatory elements and factors binding to
these sequences may reveal how these factors interact in IL-1 control of transcription of its own gene, increase our knowledge of
IL-1 signal transduction, and improve our understanding of control of
thymic development and function.
 |
ACKNOWLEDGEMENTS |
The authors are grateful to Drs. C. J. Czuprynski (Department of Pathobiological Sciences, University of
Wisconsin, Madison, WI) and T. G. Golos (Wisconsin Regional
Primate Center, University of Wisconsin, Madison, WI) for reagents and
thoughtful advice. We would like to thank Dr. H.-T. Chen (currently at
Cornell University Medical Center, New York, NY) for providing bovine
genomic library, and Erin Klaffky for her technical assistance.
 |
FOOTNOTES |
*
This work was supported by United States Department of
Agriculture Grant 96-35204-3664.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF026543
Present address: Joslin Diabetes Center, One Joslin Place, Boston,
MA 02215.
§
To whom correspondence should be addressed: Dept. of Comparative
Biosciences, 2015 Linden Drive West, Madison, WI 53706. Tel.: 608-263-9825; Fax: 608-263-3926.
1
The abbreviations used are: IL-1, interleukin 1;
TSC, thymic stromal cells; LPS, lipopolysaccharide; EMSA,
electrophoretic mobility shift assay(s); CS, consensus sequences; kbp,
kilobase pair(s); POU, pit, oct, unc.
2
Y.-H. Tseng and L. A. Schuler, unpublished
data.
 |
REFERENCES |
-
Dinarello, C. A.
(1996)
Blood
87,
2095-2147[Abstract/Free Full Text]
-
Bankers-Fulbright, J. L.,
Kalli, K. R.,
and McKean, D. J.
(1996)
Life Sci.
59,
61-83[CrossRef][Medline]
[Order article via Infotrieve]
-
Auron, P. E.,
and Webb, A. C.
(1994)
Eur. Cytokine Netw.
5,
573-592[Medline]
[Order article via Infotrieve]
-
Hedges, S. R.,
Agace, W. W.,
and Svanborg, C.
(1995)
Trends Microbiol.
3,
266-270[CrossRef][Medline]
[Order article via Infotrieve]
-
Dower, S. K.,
Sims, J. E.,
Cerretti, D. P.,
and Bird, T. A.
(1992)
Chem. Immunol.
51,
33-64[Medline]
[Order article via Infotrieve]
-
Carding, S. R.,
Hayday, A. C.,
and Bottomly, K.
(1991)
Immunol. Today
12,
239-245[CrossRef][Medline]
[Order article via Infotrieve]
-
Zlotnik, A.,
and Moore, T. A.
(1995)
Curr. Opin. Immunol.
7,
206-213[CrossRef][Medline]
[Order article via Infotrieve]
-
Gery, I.,
Gershon, R. K.,
and Waksman, B. H.
(1972)
J. Exp. Med.
136,
128-142[Abstract]
-
Gotlieb, W. H.,
Takacs, L.,
Young, H. A.,
Gusella, L.,
and Durum, S. K.
(1990)
J. Immunol.
144,
2072-2081[Abstract]
-
Herbelin, A.,
Machavoine, F.,
Vicari, A.,
Schneider, E.,
Papiernik, M.,
Ziltener, H.,
Penit, C.,
and Dy, M.
(1994)
J. Immunol.
153,
1973-1981[Abstract]
-
McConkey, D. J.,
Hartzell, P.,
Chow, S. C.,
Orrenius, S.,
and Jondal, M.
(1990)
J. Biol. Chem.
265,
3009-3011[Abstract/Free Full Text]
-
Zuniga-Pflucker, J. C.,
Jiang, D.,
and Lenardo, M. J.
(1995)
Science
268,
1906-1909[Abstract/Free Full Text]
-
Pezzano, M.,
Philp, D.,
Stephenson, S.,
Li, Y.,
Reid, V.,
Maitta, R.,
and Guyden, J. C.
(1996)
Cell. Immunol.
169,
174-184[CrossRef][Medline]
[Order article via Infotrieve]
-
Galy, A. H. M.,
Hadden, E. M.,
Touraine, J.,
and Hadden, J. W.
(1989)
Cell. Immunol.
124,
13-27[CrossRef][Medline]
[Order article via Infotrieve]
-
Galy, A. H. M.,
Dinarello, C. A.,
Kupper, T. S.,
Kameda, A.,
and Hadden, J. W.
(1990)
Cell. Immunol.
129,
161-175[CrossRef][Medline]
[Order article via Infotrieve]
-
Galy, A. H. M.,
and Spits, H.
(1991)
J. Immunol.
147,
3823-3830[Abstract]
-
Shu, S.,
Naylor, P.,
Touraine, J.,
and Hadden, J.
(1996)
Thymus
24,
89-99[Medline]
[Order article via Infotrieve]
-
Le, P. T.,
Lazorick, S.,
Whichard, L. P.,
Haynes, B. F.,
and Singer, K. H.
(1991)
J. Exp. Med.
174,
1147-1157[Abstract/Free Full Text]
-
Schluns, K. S.,
Cook, J. E.,
and Le, P. T.
(1997)
J. Immunol.
158,
2704-2712[Abstract]
-
Tseng, Y.-H.,
Kessler, M. A.,
and Schuler, L. A.
(1997)
Mol. Cell. Endocrinol.
128,
117-127[CrossRef][Medline]
[Order article via Infotrieve]
-
Dinarello, C. A.,
Ikejima, T.,
Warner, S. J. C.,
Orencole, S. F.,
Lonnemann, G.,
Cannon, J. G.,
and Libby, P.
(1987)
J. Immunol.
139,
1902-1910[Abstract]
-
Warner, S.,
Auger, K.,
and Libby, P.
(1987)
J. Exp. Med.
165,
1316-1331[Abstract/Free Full Text]
-
Warner, S. J. C.,
Auger, K. R.,
and Libby, P.
(1987)
J. Immunol.
139,
1911-1917[Abstract]
-
Tsukada, J.,
Waterman, W. R.,
Koyama, Y.,
Webb, A. C.,
and Auron, P. E.
(1996)
Mol. Cell. Biol.
16,
2183-2194[Abstract]
-
Shirakawa, F.,
Saito, K.,
Bonagura, C. A.,
Galson, D. L.,
Fenton, M. J.,
Webb, A. C.,
and Auron, P. E.
(1993)
Mol. Cell. Biol.
13,
1332-1344[Abstract/Free Full Text]
-
Fenton, M. J.
(1992)
Int. J. Immunopharmacol.
14,
401-411[CrossRef][Medline]
[Order article via Infotrieve]
-
Tsukada, J.,
Saito, K.,
Waterman, W. R.,
Webb, A. C.,
and Auron, P. E.
(1994)
Mol. Cell. Biol.
14,
7285-7297[Abstract/Free Full Text]
-
Cogswell, J. P.,
Godlevski, M. M.,
Wisely, G. B.,
Clay, W. C.,
Leesnitzer, L. M.,
Ways, J. P.,
and Gray, J. G.
(1994)
J. Immunol.
153,
712-723[Abstract]
-
Godambe, S. A.,
Chaplin, D. D.,
Takova, T.,
and Bellone, C. J.
(1994)
DNA Cell Biol.
13,
561-569[Medline]
[Order article via Infotrieve]
-
Zhang, Y.,
and Rom, W. N.
(1993)
Mol. Cell. Biol.
13,
3831-3837[Abstract/Free Full Text]
-
Buras, J. A.,
Monks, B. G.,
and Fenton, M. J.
(1997)
J. Immunol.
152,
4444-4454[Abstract]
-
Kominato, Y.,
Galson, D. L.,
Waterman, W. R.,
Webb, A. C.,
and Auron, P. E.
(1995)
Mol. Cell. Biol.
15,
58-68
-
Donnelly, R. P.,
Fenton, M. J.,
Finbloom, D. S.,
and Gerrard, T. L.
(1990)
J. Immunol.
145,
569-575[Abstract]
-
Bonizzi, G.,
Dejardin, E.,
Piret, B.,
Piette, J.,
Merville, M.-P.,
and Bours, V.
(1996)
Eur. J. Biochem.
242,
544-549[Medline]
[Order article via Infotrieve]
-
Husmann, M.,
Jehnichen, P.,
Jahn, B.,
Schlosshan, D.,
Romahn, E.,
and Marx, J.
(1996)
Eur. J. Immunol.
26,
3008-3014[Medline]
[Order article via Infotrieve]
-
Koyama, Y.,
Tanaka, Y.,
Saito, K.,
Abe, M.,
Nakatsuka, K.,
Morimoto, I.,
Auron, P. E.,
and Eto, S.
(1996)
J. Immunol.
157,
5097-5103[Abstract]
-
Godambe, S. A.,
Chaplin, D. D.,
and Bellone, C. J.
(1993)
Cytokine
5,
327-335[CrossRef][Medline]
[Order article via Infotrieve]
-
Scott, P.,
and Schuler, L. A.
(1994)
Program of the 76th Annual Meeting of the Endocrine Society, Anaheim, California, June 15-18, 1994, The Endocrine Society Press, Bethesda, MD, Abst. 1405
-
Chase, C. L. C.,
Lohff, C.,
and Letchworth, G. J.
(1993)
Virology
194,
365-369[CrossRef][Medline]
[Order article via Infotrieve]
-
Yu, P.-W.,
Chen, H.-T.,
Czuprynski, C. J.,
and Schuler, L. A.
(1997)
Cytokine
9,
1-8[CrossRef][Medline]
[Order article via Infotrieve]
-
Maliszewski, C. R.,
Baker, P. E.,
Schoenborn, M. A.,
Davis, B. S.,
Cosman, D.,
Gillis, S.,
and Cerretti, D. P.
(1988)
Mol. Immunol.
25,
429-437[CrossRef][Medline]
[Order article via Infotrieve]
-
Devereux, J.,
Haberli, P.,
and Smithies, O.
(1984)
Nucleic Acids Res.
12,
687-695
-
Kingston, R. E.,
Chen, C. A.,
and Okayama, H.
(1990)
in
Current Protocols in Molecular Biology (Ausubel, F. M., ed), pp. 9.1.1-9.1.3, Wiley Interscience, New York
-
Andrews, N. C.,
and Faller, D. V.
(1991)
Nucleic Acids Res.
19,
2499[Free Full Text]
-
Wegner, M.,
Drolet, D. W.,
and Rosenfeld, M. G.
(1993)
Curr. Opin. Cell Biol.
5,
488-498[CrossRef][Medline]
[Order article via Infotrieve]
-
Martin, G.,
and Orkin, S. H.
(1990)
Genes Dev.
4,
1886-1898[Abstract/Free Full Text]
-
Gouilleux, F.,
Pallard, C.,
Dusanter-Fourt, I.,
Wakao, H.,
Haldosen, L.-A.,
Norstedt, G.,
Levy, D.,
and Groner, B.
(1995)
EMBO J.
14,
2005-2013[Medline]
[Order article via Infotrieve]
-
Lederer, J.,
and Czuprynski, C.
(1993)
Mol. Immunol.
30,
191-196[CrossRef][Medline]
[Order article via Infotrieve]
-
Peltz, S. W.,
and Jacobson, A.
(1992)
Curr. Opin. Cell Biol.
4,
979-983[CrossRef][Medline]
[Order article via Infotrieve]
-
Clark, B. D.,
Collins, K. L.,
Gandy, M. S.,
Webb, A. C.,
and Auron, P. E.
(1996)
Nucleic Acids Res.
14,
7897-7914[Abstract/Free Full Text]
-
Chodosh, L. A.
(1993)
in
Current Protocols in Molecular Biology (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K., eds), pp. 12.2.1-12.2.10, John Wiley & Sons, Inc., Brooklyn, NY
-
Herr, W.,
and Cleary, M. A.
(1995)
Genes Dev.
9,
1679-1693[Free Full Text]
-
Ryan, A. K.,
and Rosenfeld, M. G.
(1997)
Genes Dev.
11,
1207-1225[Free Full Text]
-
Shivdasani, R. A.,
and Orkin, S. H.
(1996)
Blood
87,
4025-4039[Free Full Text]
-
Scheidereit, C.,
Cromlish, J. A.,
Gerster, T.,
Kawakami, K.,
Balmaceda, C. G.,
Currie, R. A.,
and Roeder, R. G.
(1988)
Nature
336,
551-557[CrossRef][Medline]
[Order article via Infotrieve]
-
Delhase, M.,
Castrillo, J.-L.,
de la Hoya, M.,
Rajas, F.,
and Hooghe-Peters, E. L.
(1996)
J. Biol. Chem.
271,
32349-32358[Abstract/Free Full Text]
-
Staudt, L. M.,
and Lenardo, M. J.
(1991)
Annu. Rev. Immunol.
9,
373-398[CrossRef][Medline]
[Order article via Infotrieve]
-
Ullman, K. S.,
Flanagan, W. M.,
Edwards, C. A.,
and Crabtree, G. R.
(1991)
Science
254,
558-562[Abstract/Free Full Text]
-
Kaushansky, K.,
Shoemaker, S. G.,
O'Rork, C. A.,
and McCarty, J. M.
(1994)
J. Immunol.
142,
1812-1820
-
Wu, G. D.,
Lai, E. J.,
Huang, N.,
and Wen, X.
(1997)
J. Biol. Chem.
272,
2396-2403[Abstract/Free Full Text]
-
Newton, R.,
Adcock, I. M.,
and Barnes, P. J.
(1996)
Biochem. Biophys. Res. Commun.
218,
518-523[CrossRef][Medline]
[Order article via Infotrieve]
-
Martin, M. U.,
and Falk, W.
(1997)
Eur. Cytokine Netw.
8,
5-17[Medline]
[Order article via Infotrieve]
-
Grenfell, S. J.,
Latchman, D. S.,
and Thomas, N. S. B.
(1996)
Biochem. J.
315,
889-893
-
Segil, N.,
Roberts, S. B.,
and Heintz, N.
(1991)
Science
254,
1814-1816[Abstract/Free Full Text]
-
Bungert, J.,
and Engel, J. D.
(1996)
Ann. Med.
28,
47-55[Medline]
[Order article via Infotrieve]
-
Grace, T. M.,
Roth, M. E.,
Groskopf, J. C.,
Tsai, F.-Y.,
Orkin, S. H.,
Grosveled, F.,
Engel, J. D.,
and Linzer, D. I. H.
(1997)
Development
124,
907-914[Abstract]
-
Pandolfi, P. P.,
Roth, M. E.,
Karis, A.,
Leonard, M. W.,
Dzierzak, E.,
Engel, J. D.,
and Lindenbaum, M. H.
(1995)
Nat. Genet.
11,
40-44[CrossRef][Medline]
[Order article via Infotrieve]
-
Hattori, N.,
Kawamoto, H.,
Fujimoto, S.,
Kuno, K.,
and Katsura, Y.
(1996)
J. Exp. Med.
184,
1137-1147[Abstract/Free Full Text]
-
Tsang, A. P.,
Visvader, J. E.,
Turner, C. A.,
Fujiwara, Y.,
Yu, C.,
Weiss, M. J.,
Crossley, M.,
and Orkin, S. H.
(1997)
Cell
90,
109-119[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
I. Miyata, S. Vallette-Kasic, A. Saveanu, M. Takeuchi, H. Yoshikawa, A. Tajima, K. Tojo, R. Reynaud, M. Gueydan, A. Enjalbert, et al.
Identification and Functional Analysis of the Novel S179R POU1F1 Mutation Associated with Combined Pituitary Hormone Deficiency
J. Clin. Endocrinol. Metab.,
December 1, 2006;
91(12):
4981 - 4987.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Al-Mohanna, S. Saleh, R. S. Parhar, K. Khabar, and K. Collison
Human neutrophil gene expression profiling following xenogeneic encounter with porcine aortic endothelial cells: the occult role of neutrophils in xenograft rejection revealed
J. Leukoc. Biol.,
July 1, 2005;
78(1):
51 - 61.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Brockman, M. D. Schroeder, and L. A. Schuler
PRL Activates the Cyclin D1 Promoter Via the Jak2/Stat Pathway
Mol. Endocrinol.,
April 1, 2002;
16(4):
774 - 784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Schroeder, J. Symowicz, and L. A. Schuler
PRL Modulates Cell Cycle Regulators in Mammary Tumor Epithelial Cells
Mol. Endocrinol.,
January 1, 2002;
16(1):
45 - 57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Andersen and M. G. Rosenfeld
POU Domain Factors in the Neuroendocrine System: Lessons from Developmental Biology Provide Insights into Human Disease
Endocr. Rev.,
February 1, 2001;
22(1):
2 - 35.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
T. Kordula, M. Bugno, R. E. Rydel, and J. Travis
Mechanism of Interleukin-1- and Tumor Necrosis Factor alpha -Dependent Regulation of the alpha 1-Antichymotrypsin Gene in Human Astrocytes
J. Neurosci.,
October 15, 2000;
20(20):
7510 - 7516.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|